In a survey released by oncology data leader COTA, half of the respondents pointed to “Operation Warp Speed” for the Covid-19 pandemic as the seed of their belief that cancer treatments can and should be moving forward faster.
Public safety is the world’s singular goal as mandatory quarantines, shelter-in-place orders, travel restrictions, and mandatory work-from-home policies go into effect to curb the spread of COVID-19. In response, many biopharmaceutical companies are shifting how they work: Amarin withdrew part of its field force, while Amgen and Merck have instructed their sales teams to halt all in-person meetings with physicians and hospitals.
Navigating your brand through COVID-19Ad agency blogging, April 2020, Brands, Consumers, Coronavirus Disease (COVID-19) Pandemic, Customers, Departments, Dermatologists, Digital, Facebook, HCPs, Healthcare Communications Agencies, Marketing & Advertising, Med Ad News, Medicine Avenue, Oncologists, Patients, Sales Reps, Social media, Telemedicine
In these days of the COVID-19 epidemic, many in the pharma industry are facing the challenge of accessing their customers and engaging in communication. The good news is that there are virtual solutions and approaches that are proven to deliver when in-person selling is limited or no longer an option.
Branding is the art and discipline of taking values that customers esteem and transferring them to a product, service or company so customers see a flattering reflection of themselves in the brand. A brand of car that owns the idea of safety will attract safe drivers, which in turn will reinforce the vehicle brand’s identity, and so on.
The U.S. Senate confirmed Stephen Hahn as commissioner of the U.S. Food and Drug Administration in a 72-18 vote.
U.S. President Donald Trump plans to nominate Dr. Stephen Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the Food and Drug Administration.
In the halls of MD Anderson Cancer Center, Vitrakvi is known for having a “Lazarus effect” in some patients because the drug can reverse late-stage cancer that has defied all other treatment options.
British Columbia-based Chinook Therapeutics burst onto the scene with $65 million in hand and a goal of driving a portfolio of compounds aimed at kidney diseases into the clinic by 2021.
Cancer drug study patients tend to be younger than most people with the disease in the general population.
What if we could look inside the minds of HCPs to see what is happening there during industry events and interactions?